Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6167 Target Snapshot

Serine/threonine-protein kinase LATS1 · SINGLE PROTEIN · Homo sapiens

784Compounds
172Assays
7Approved Drugs
958.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O95835. Use UniProt O95835 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O95835 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase LATS1 as ChEMBL target CHEMBL6167, mapped to UniProt O95835. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase LATS1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL6167
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O95835
Serine/threonine-protein kinase LATS1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase LATS1 is the right protein anchor across sources, using UniProt O95835 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase LATS1
UniProt AccessionO95835
Component TypeProtein
Sequence Length1130 aa

Serine/threonine-protein kinase LATS1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase LATS1, mapped to UniProt O95835. Sequence length is 1130 aa.

Mapped IDO95835
Review nameSerine/threonine-protein kinase LATS1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

7
Approved
9
Phase III
7
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC50593.0
KD365.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4439972 9.15 IC50 0.7 Preclinical
CHEMBL4447153 9.1 IC50 0.8 Preclinical
CHEMBL4525078 9.1 IC50 0.8 Preclinical
CHEMBL4463018 9.05 IC50 0.9 Preclinical
CHEMBL4463415 9.05 IC50 0.9 Preclinical
CHEMBL4443335 9.0 IC50 1.0 Preclinical
CHEMBL4444109 9.0 IC50 1.0 Preclinical
CHEMBL4446730 9.0 IC50 1.0 Preclinical
CHEMBL4450439 9.0 IC50 1.0 Preclinical
CHEMBL4450447 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

15
5.0
28
5.5
44
6.0
48
6.5
81
7.0
103
7.5
133
8.0
92
8.5
57
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

GILTERITINIB
CHEMBL3301622
Approved 2018
NINTEDANIB
CHEMBL502835
Approved 2014
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

172
Total Assays
369
Tested Compounds
1
Assay Types
Binding — 172 assays, 369 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 94 296 7.8
cell-based format 33 0
assay format 24 44 7.9
subcellular format 21 29 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine